[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100511896":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":25,"centralContacts":29,"locations":34,"responsibleParty":52,"collaborators":56,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":24,"eligibilityCriteria":81,"healthyVolunteers":77,"sex":82,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":24,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":98,"overallStatus":37,"whyStopped":24,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":113},{"fullName":5,"class":6},"Peking University People's Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Myometrial invasion group","EXPERIMENTAL","Pelvic enhanced magnetic resonance imaging or transvaginal color Doppler ultrasound suggests that the tumor invades less than one half of the myometrium.",[13],"Combination Product: Indication-extended Fertility-sparing Therapy",{"label":15,"type":6,"description":16,"interventionNames":17},"No myometrial invasion group","Pelvic enhanced magnetic resonance imaging or transvaginal color Doppler ultrasound suggests that the tumor is limited to the endometrium.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"COMBINATION_PRODUCT","Indication-extended Fertility-sparing Therapy","Patients will receive medroxyprogesterone acetate (\"FARLUTAL\") 250-500mg\u002Fd or megestrol acetate (\"YiLiZhi\") 160-320mg\u002Fd orally. If there is no response after 6 months of treatment, change the regimen to levonorgestrel intrauterine system (\"Mirena\") and gonadotropin-releasing hormone agonist (\"Leuprorelin\", \"Goserelin\" or \"Triptorelin\") 3.75mg\u002F28d injection subcutaneously. After complete remission, the same regimen will be used for consolidation treatment for another 1-3 months. Subsequently, if the patient has no intention of pregnancy, render maintenance treatment (\"Mirena\", \"Progesterone\", \"Dydrogesterone\", or combined oral contraceptive). Otherwise, the patient will be encouraged to conceive either by an expectation for 3-6 months, or by assisted reproductive technology. Indications for stopping fertility-sparing therapy: 1) disease progression; 2) no response after 9 months of treatment; 3) repeated recurrence; 4) no longer require sparing fertility; 5) serious adverse reactions.",[9,15],null,[26],{"name":27,"affiliation":5,"role":28},"Jianliu Wang, Professor","STUDY_DIRECTOR",[30],{"name":27,"role":31,"phone":32,"phoneExt":24,"email":33},"CONTACT","0086-010-88324381","wangjianliu1203@163.com",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Peking University People's Hosoital","RECRUITING","Beijing","Beijing Municipality","100044","China","CN",{"type":44,"coordinates":45},"Point",[46,47],116.39723,39.9075,{"lat":47,"lon":46},[50],{"name":27,"role":31,"phone":32,"phoneExt":24,"email":51},"wangjianliu@pku.edu.cn",{"type":53,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"PRINCIPAL_INVESTIGATOR","Wang Jianliu","Chief physician",[57,59,61,63,65,67,69,71,73],{"name":58,"class":6},"Peking University Third Hospital",{"name":60,"class":6},"Peking Union Medical College Hospital",{"name":62,"class":6},"Third Military Medical University",{"name":64,"class":6},"Tianjin Medical University General Hospital",{"name":66,"class":6},"Tongji Hospital",{"name":68,"class":6},"Qilu Hospital of Shandong University",{"name":70,"class":6},"Shengjing Hospital",{"name":72,"class":6},"Beijing Chao Yang Hospital",{"name":74,"class":6},"Guang'anmen Hospital of China Academy of Chinese Medical Sciences","100511896","fertility-sparing-therapy-for-patients-with-stage-ia-endometrial-cancer-100511896",false,"NCT05945407","Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer","Establishment of a Network Platform for Fertility-sparing in Patients With Endometrial Cancer and Study on Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer.","Inclusion Criteria:\n\n* Stage IA (FIGO 2009) ;\n* Pathological diagnosis: endometrial adenocarcinoma G1-G2;\n* MRI or ultrasound: tumor limited to endometrium or invading less than 1\u002F2 of myometrium；\n* 18 years old ≤ Age ≤ 45 years old;\n* With a strong desire for fertility preservation；\n* Sign the informed consent.\n\nExclusion Criteria:\n\n* Complicated with any other malignancy；\n* Contraindications to conservative treatment；\n* Contraindications to progestin use;\n* Contraindications to pregnancy, or judged by the researcher to be unfit for pregnancy or delivery.","FEMALE","18 Years","45 Years",{"count":86,"type":87},57,"ESTIMATED","INTERVENTIONAL",[90],"NA","The goal of this clinical trial is to explore the feasibility and outcome of fertility-sparing therapy in Stage IA G1-G2 Endometrial Cancer with less than 1\u002F2 myometrial invasion. Researchers will render participants indication-extended fertility-sparing therapy. Researchers will compare the myometrial invasion group with the no myometrial invasion group to see if it is possible to propose an extension indication of fertility-sparing therapy for endometrial cancer.",[93,94,95,96,97],"Endometrial Neoplasms","Endometrial Neoplasm Malignant","Endometrial Neoplasm Malignant Stage I","Carcinoma, Endometrioid","Fertility Preservation",[99,100,101,102,103],"Fertility-sparing","Fertility-preserving","Endometrial Carcinoma","Endometrial Cancer","Indication Extension","2023-07-12",{"date":106,"type":107},"2023-07-14","ACTUAL",{"date":109,"type":107},"2016-08-01",{"date":111,"type":87},"2027-12-31",{"name":5,"class":6},1]